Skilled reaching deterioration contralateral to cervical hemicontusion in rats is reversed by pregabalin treatment conditional upon its early administration

Erin L.K.S. Erskinea, Brittney D. Smailaa, Ward Pluneta, Jie Liu, Elizabeth E. Raffaelea, Wolfram Tetzlaffab, John L.K. Kramerac, Matt S. Ramera,b,*

Abstract
Introduction: Gabapentinoids are first-line treatments for painful traumatic and nontraumatic central nervous system disorders. Evidence from a large human study suggests that early use of gabapentinoids after spinal cord injury improves motor scores. The underlying mechanism is unknown.

Objectives: We sought to examine the effects of early pregabalin (PGB, a gabapentinoid) treatment on performance in a fine motor task (skilled reaching) after cervical hemicontusion. We also asked whether early PGB administration affected PGB responsiveness later on.

Methods: Rats received C4/5 cervical hemicontusions. Injury severities ranged from 80 to 150 kdyn. We monitored evidence of skin irritation (peri-incisional and elsewhere) and quantified food pellet retrieval using the Montoya staircase test. Behaviours were assessed in rats receiving early (for 3 weeks from injury induction) and/or late (resuming or beginning at week 8) PGB treatment in animals with 150-kdyn injuries.

Results: Contralateral skilled reaching waned in control animals with 150-kdyn injuries. This was prevented in animals, which received early PGB as long as treatment continued. Deterioration of skilled reaching was reversed by later (week 8) PGB only in animals that had received early treatment. Ipsilateral reaching impairment was not improved by PGB. Relief of skin irritation verified early PGB efficacy.

Conclusion: Hemicontusive spinal cord injury produces a contralateral motor phenotype evocative of on-going neuropathic pain. Early PGB preserves sensitivity to subsequent PGB treatment, indicating that motor function is impaired by neuropathic pain and can be improved indirectly by early PGB administration. Direct effects of PGB on motor circuitry cannot be excluded but are not supported by our data.

Keywords: Spinal cord injury, Pregabalin, Rats, Skilled reaching, Tonic pain

1. Introduction
Neuropathic pain is a concern for many people with spinal cord injury (SCI), emphasizing a need for its study in animal models. Here, we report on a novel behavioural consequence of SCI, probably reflecting a state of on-going neuropathic pain, arising in a rat model of cervical spinal hemicontusion. This injury results in incomplete destruction of ipsilateral gray and white matter, sparing contralateral spinal tissue.

This work was motivated by results from a large clinical cohort showing that early gabapentinoid treatment led to improved muscle strength over the first year after injury. The mechanism is unknown, but the simplest explanation would be a direct effect on injured motor circuitry. We investigated the effects of early pregabalin (PGB, a gabapentinoid) treatment after cervical hemicontusion to model clinical findings, and as a first step toward linking its potential neuroprotective or regenerative effects to fine motor function (skilled forepaw reaching). The results, however, suggest that early PGB’s effect on later (contralateral) motor improvement rely on preservation of its ability to modulate neuropathic pain.

2. Methods
2.1. Animals
All procedures conformed to guidelines of the Canadian Council on Animal Care and were approved by our institutional Animal Care Committee. We started with 40 Sprague-Dawley rats.
(282–395 g). Two died during surgery; another reached humane end-point 2 to 4 weeks later. Additional behavioural data from control arms of other studies in our centre were collected from 104 Sprague–Dawley rats of similar weights. All injuries were made using the Infinite Horizon Impactor (model IH-0400; Precision Systems and Instrumentation LLC, Fairfax Station, VA) as per Lee et al. Contusions for the PGB study were delivered with a force of 150 kdyn. Other data were collected from 40 rats with identical injuries (20 each from 2 independent experiments), from 14 rats with 80-kdyn injuries, 16 rats with 100-kdyn injuries, and 34 rats with 120-kdyn injuries (20 and 14 from 2 independent experiments). In all cases, the injury was made on the rats’ dominant sides (see below). All rats received identical perioperative care and monitoring. An additional group of sham-operated rats (n = 9) was used to monitor surgery-associated skin irritation.

2.2. Pregabalin treatment

Rats received either filtered water or 34 mg/kg of PGB (TEVA Canada Limited, Toronto, ON, Canada) in filtered water through gavage at 12-hour intervals, beginning 1 hour after surgery. This is similar to that used to prompt axonal regeneration in mice (46 mg/kg). Treatment ceased 12 to 24 hours before week 4 of behavioural testing. Pregabalin treatment resumed (or began) in all animals at the beginning of the eighth postoperative week.

2.3. Behavioural testing

All data were collected in a blinded fashion. Fine motor function was assessed with the Montoya staircase test. Handedness was determined for each animal (on the penultimate of 12 training sessions over 6 weeks—the ultimate was considered baseline). Postoperative testing was performed at the end of weeks 2, 4, 6, 7 (PGB study only), and 8.

2.4. Statistics

Evidence of skin irritation (wet wounds or fresh scabs around the incision or elsewhere) was collected from monitoring charts and is presented as proportion of animals. Biweekly comparisons were made between vehicle and PGB-treated groups (χ² tests). Significant differences (P < 0.05) are indicated (Fig. 1).

Skilled reaching success is reported as percent of pellets retrieved (individually and mean ± SE). Comparisons were made in Prism 8 (GraphPad) between baseline and postoperative success rates using a one-way RM analysis of variance followed by Dunnett test. We compared retrieval success between PGB- and vehicle-treated animals at 2, 4, and 6 weeks using unpaired two-tailed t tests. We used a paired two-tailed t test to compare success values at 7 (all untreated) and 8 (all PGB-treated) weeks for (1) all animals and (2) separately for animals which had had early vehicle or early PGB. We also tested for linear trend over the entire postoperative period for all studies. Exact P values are shown (Fig. 2).

3. Results

3.1. Skin irritation

All spinal cord–injured animals showed evidence of peri-incisional scratching after SCI, irrespective of injury severity (Fig. 1A). This was also evident in sham-operated animals, but earlier and with greater prevalence than in animals with SCI, probably because of spared motor function. A small proportion of animals (<20%) with 150-kdyn injuries also had lesions around the ipsilateral ear, in the territory of the great auricular nerve (which projects centrally to the first 4 cervical segments). Early PGB treatment significantly reduced the prevalence of peri-incisional scratching, in-line with known effects of PGB on postoperative pain and pruritus.

3.2. Montoya staircase pellet retrieval

Fifty-nine percentage of all rats were left-handed. After 150-kdyn injuries (60% lefties), but not 80-, 100-, or 120-kdyn injuries, there was a progressive decline in skilled reaching contralaterally (Fig. 2). Tests for linear trend showed statistical significance for 3 independent data sets (2 in Fig. 2A, and the vehicle arm of Fig. 2B, 59 animals in total). Pregabalin treatment prevented the initial decline in reaching success (Fig. 2B), but its cessation (before week 4) resulted in worsened performance, statistically equivalent to that of vehicle-treated rats. Resuming or starting PGB treatment at the beginning of week 8 resulted in reaching success one week later that was significantly greater than that at week 7 (P = 0.0085, all animals, paired t test). Reaching success with late PGB treatment only improved in animals that had received early PGB (Fig. 2C, P = 0.0084, paired t test). Pregabalin had no effect on ipsilateral reaching (Fig. 2D).

4. Discussion

This study shows that after cervical hemicontusion: skilled reaching contralateral to injury worsens with time; early PGB treatment prevents the initial decline but only as long as treatment continues; and improvement is conferred by delayed PGB treatment only in animals which received early PGB. Relief of skin irritation by PGB confirmed efficacy. Our data argue that PGB does not cause sedation (increased pellet retrieval despite reduced scratching at week 2) nor does it motivate pellet retrieval by increasing appetite. Although other motivational issues such as anhedonia or learned helplessness are possible, on balance, the data suggest that neuropathic pain interferes with execution of fine movement.

Anticonvulsants like PGB are first-line analgesic treatments for traumatic and nontraumatic central nervous system disorders. Pregabalin binds to ε28 subunits of presynaptic voltage-sensitive calcium channels, but its analgesic effect probably relies on some other mechanism since its concentration in cerebral spinal fluid reaches maximum concentration ~8 hours after oral administration, and yet, it takes several days for efficacy. Furthermore, clinically relevant doses do not inhibit transmission acutely in the dorsal horn.

Patients prescribed PGB within 3 months of SCI had a higher motor score 1-year after injury than those prescribed PGB later. But how? By direct effects on ability to move, or indirectly by some other mechanism? Although the clinical study did not find any relationship between pain and motor function with early PGB, gabapentinoid status at the time of assessment was unknown, potentially masking effects we have uncovered here. In addition to its anticonvulsant and analgesic effects, recent data highlight PGB as neuroprotective in models of multiple sclerosis, facial nerve injury, and epilepsy, and as proregenerative for ascending dorsal column axons after SCI.
Figure 1. (A) Skin irritation after cervical hemicontusion. Scratching near the incision site occurred regardless of injury severity, while scratching behind the ipsilateral ear occurred in some animals with more severe injuries. In spinal-intact sham-operated animals, scratching was more prevalent and occurred earlier than in those with SCI. (B) Schematic indicating treatment groups and animal numbers. “PG off” (magenta) refers to animals that had had PGB treatment starting at the time of injury. (C) PGB delayed the onset and reduced the prevalence of peri-incisional scratching (*P < 0.05, χ² test). PGB, pregabalin; SCI, spinal cord injury.
Figure 2. (A) Pellet retrieving ability contralateral to a cervical hemicontusion. With more severe injury, there was a progressive reduction in pellet retrieval success. Filled and open symbols represent 2 independent experiments each at 120 and 150 kdyn. *Significant differences from baseline (one-way analysis of variance followed by Dunnett test for multiple comparisons). Linear trends were $P < 0.0001$ for both 150-kdyn experiments. (B) Early PGB treatment (green) prevented the initial decline in contralateral pellet retrieving ability (asterisk at 2 weeks, two-tailed unpaired $t$ test), but cessation abolished this effect. Later, PGB treatment improved retrieval ability (asterisk between weeks 7 and 8, two-tailed paired $t$ test). Magenta-filled symbols indicate animals that had received early PGB but were removed from treatment between weeks 4 and 7. (C) Retrospective analysis of weeks 7 and 8 data revealed that only those animals that had received early PGB were responsive to later PGB treatment (two-tailed paired $t$ test). (D) Neither early nor late PGB treatment affected ipsilateral pellet retrieving ability. PGB, pregabalin.
tract (STT): incomplete STT damage is believed to be a prerequisite for SCI-induced neuropathic pain.7,8,30 Clinically, con- tusive STT-sparing hemicord lesions are rare but can result in contralateral prunitus27 and neuropathic pain.16 For these reasons, we suggest that progressive deterioration of contralat- eral reaching relies on residual but abnormal STT function, an idea that could be tested in the future using complete (STT-severing) spinal hemisection. The absence of any ipsilateral influence of PGB also argues against a direct effect on motor circuitry. A “basement” effect might be postulated, but we have previously shown that ipsilateral skilled reaching after 150-kdyn hemi- contusions can be improved through therapeutic intervention.25,26

Studying SCI-induced neuropathic pain in experimental animals is notoriously difficult because of reliance on responses to peripheral stimulation.13 Such measures are problematic because of hyper-reflexia,28 and their questionable relevance to pain after experimental SCI in rats have involved exploratory behaviour18 or conditioned place preference.31 The time course of declining reaching ability shown here corresponds well with gabapentinoid-sensitive decreases in exploratory behaviour,18 further bolstering the idea that worsening skilled reaching reflects neuropathic pain. In people, symptoms are also progressive and persistent.4,22

In conclusion, cervical spinal hemicontusion reduces con- tralateral skilled reaching probably as a result of neuropathic pain associated with STT damage. Early PGB treatment not only prevents the initial decline in ability but also preserves sensitivity to PGB. Whether this relies on structural neuroprotection (ie, tissue sparing) or otherwise remains to be determined. In addition to stressing the importance of early pain intervention after SCI,5 these data offer an explanation for beneficial effects of early PGB on clinically demonstrated improvements in motor scores.29

Disclosures
The authors have no conflict of interest to declare.

Acknowledgements
The authors are grateful to Nicole Janzen for technical leadership. Support was received by the British Columbia Neurotrauma Fund Professorship (M.S.R.), the International Foundation for Research in Paraplegia (M.S.R.), Wings for Life (M.S.R. and J.L.K.R.), the Canadian Institutes of Health Research (J.L.K.R.), the Rick Hansen Foundation through the ICORD-Rick Hansen Institute—Blusson Integrated Cure Partnership (W.T.), and the John and Penny Ryan BC Leadership Chair (W.T.).

Article history:
Received 22 January 2019
Received in revised form 28 March 2019
Accepted 1 April 2019

References
[1] Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma 2004;21:1371–83.
[2] André V, Rigoulot MA, Koning E, Fernand0 A, Nehlig A. Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia 2003;44:893–903.
[3] Baba H, Petrenko AB, Fujiwara N. Clinically relevant concentration of pregabalin has no acute inhibitory effect on excitation of dorsal horn neurons under normal or neuropathic pain conditions: an intracellular calcium-imaging study in spinal cord slices from adult rats. Brain Res 2016;1648:445–58.
[4] Baiydi DK, Agnanial A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol 2011;27:307–14.
[5] Buvanendran A, Kroin JS, Kari M, Tuman KJ. Can a single dose of 300 mg of pregabalin reach acute antinociceptive levels in the central nervous system? Reg Anesth Pain Med 2010;35:535–8.
[6] Cragg JJ, Haefeli J, Jutzeler CR, Röhrich F, Weidner N, Saur M, Maier DD, Kalke YB, Schuld C, Curt A, Kramer JK. Effects of pain and pain management on motor recovery of spinalcord-injured patients: a longitudinal study. Neurorehabil Neural Repair 2016;30:753–61.
[7] Cruz-Almeida Y, Felix ER, Martínez-Arizala A, Wiederstrom-Noga EG. Decreased spinothalamic and dorsal column medial lemniscus-mediated function is associated with neuropathic pain after spinal cord injury. J Neurotrauma 2012;29:2706–15.
[8] Defrin R, Otry A, Blumen N, Urca G. Characterization of chronic pain and somatosensory function in spinal cord injury subjects. PAIN 2001;89:253–63.
[9] Foroutan N, Nikzar N. Role of pregabalin in management of pruritus: a literature review. J Pharm Pharm Sci 2016;19:465–74.
[10] Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448–54.
[11] Hundehepe P, Fernandez-Orth J, Romer P, Ruck T, Munterfering T, Eichler S, Gerina M, Epping L, Albrecht S, Menke AF, Birkner K, Gobel K, Budde T, Zipp F, Wiendl H, Goori A, Bittner S, MOUTH SG. Targeting voltage-dependent calcium channels with pregabalin exerts a direct neuroprotective effect in an animal model of multiple sclerosis. Neurosignals 2018;26:77–93.
[12] Irving G, Tanenberg RJ, Raskin J, Risser RC, Malcolm S. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Int J Clin Pract 2014;68:111–40.
[13] Kramer JL, Minhas NK, Jutzeler CR, Erskine ELKS, Liu LWJ, Ramer MS. Neuropathic pain following traumatic spinal cord injury: models, measurement, and mechanisms. J Neurosci Res 2016;95:1295–1306.
[14] Lee JH, Streiger F, Tiggelhaar S, Malon M, Liu J, Tetzlaff W, Kwon BK. A combitive model of unilateral cervical spinal cord injury using the infinite horizon impactor. J Vis Exp 2012;66:pii: 3313.
[15] Liu D, Hu Y. The central projections of the great auricular nerve primary afferent fibers—an HRP transganglionic tracing method. Brain Res 1988;445:205–10.
[16] Loch-Wilkinson T, McNeil S, White C, Schrag C, Midha R. Nerve transfers in patients with brown-sequard pattern of spinal cord injury: report of 2 cases. World Neurosurg 2018;110:152–7.
[17] Matsuda KM, Sharma D, Schonfeld AF, Kwarat SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol 2016;75:619–e6.
[18] Mills CD, Grady JJ, Hulsebosch CE. Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. J Neurotrauma 2001;18:1091–105.
[19] Montoya OP, Campbell-Hope LJ, Pemberton KD, Dunnett SB. The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991;36:219–28.
[20] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[21] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[22] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[23] Morrisy S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[24] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[25] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[26] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[27] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[28] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[29] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[30] Moriya S, Hasegawa M, Inamasu J, Kogame H, Hirose Y, Higashi R, Ito M, Imai F. Neuroprotective effects of pregabalin in a rat model of intracranial central pain avulsion. J Neurosurg Sci 2017;61:495–503.
[26] Tedeschi A, Dupraz S, Laskowski CJ, Xue J, Ulas T, Beyer M, Schultze JL, Bradke F. The calcium channel subunit Alpha2delta2 suppresses axon regeneration in the adult CNS. Neuron 2016;92:419–34.

[27] Thielen AM, Vokatch N, Borradori L. Chronic hemicorporal prurigo related to a posttraumatic Brown-Séquard syndrome. Dermatology (Basel) 2008;217:45–7.

[28] van Gorp S, Deumens R, Leerink M, Nguyen S, Joosten EA, Marsala M. Translation of the rat thoracic contusion model; part 1-supraspinally versus spinally mediated pain-like responses and spasticity. Spinal Cord 2014;52:524–8.

[29] Warner FM, Cragg JJ, Jutzeler CR, Rohrich F, Weidner N, Saur M, Maier DD, Schuld C, Sites E, Curt A, Kramer JK. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep 2017;18:1614–18.

[30] Wasner G, Lee BB, Engel S, McLachlan E. Residual spinothalamic tract pathways predict development of central pain after spinal cord injury. Brain 2008;131:2387–400.

[31] Yang Q, Wu Z, Hadden JK, Odem MA, Zuo Y, Crock RJ, Frost JA, Walters ET. Persistent pain after spinal cord injury is maintained by primary afferent activity. J Neurosci 2014;34:10765–9.